Their lead drug candidate, micvotabart pelidotin (MICVO) , has received FDA Fast Track Designation for head and neck cancer. Preliminary Phase 1 clinical data is expected to be a major "make-or-break" milestone in late 2025 and through 2026. Zentalis Pharmaceuticals (ZNTL) Sector: Healthcare (Biotechnology) Current Price: Approximately $3.74

Analysts maintain a "Strong Buy" consensus with a median price target of $7.20 , suggesting a massive 309% upside .

The company provides vital thermal management for batteries in electric vehicles and 5G infrastructure. It recently reported a 44% year-over-year revenue increase for its most recent fiscal quarter. Market Summary: Key Penny Stocks at a Glance Company Name Approx. Price Key Strength Valens Semiconductor Technology Debt-free; automotive design wins Pyxis Oncology Healthcare FDA Fast Track; 300%+ target upside Zentalis Pharma Healthcare Late-stage cancer trial data pending KULR Technology Technology 44% YoY revenue growth Bitfarms Ltd. Crypto Mining Energy-efficient BTC mining fleet Risk Factors to Consider